Safety and Immunogenicity of Two Doses, Administered Three Weeks Apart, of Two Monovalent H5N1 Influenza Vaccines Containing 2 Doses of H5N1 Influenza Antigen, in Non-elderly Adult and Elderly Subjects

NCT00914771 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

722

Enrollment

INDUSTRY

Sponsor class

Conditions

Pandemic H5N1 Influenza

Interventions

BIOLOGICAL: H5N1 pandemic Influenza vaccine 3.75µg
BIOLOGICAL: H5N1 pandemic Influenza vaccine 7.5µg

Sponsor

Novartis Vaccines